Agile Therapeutics Inc. (NASDAQ:AGRX)’s share price was down 3.4% on Tuesday . The stock traded as low as $6.86 and last traded at $7.11, with a volume of 400,220 shares changing hands. The stock had previously closed at $7.36.

Several equities analysts recently weighed in on AGRX shares. FBR & Co restated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. Cantor Fitzgerald restated a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.00.

The company’s 50 day moving average is $7.12 and its 200-day moving average is $6.61. The firm’s market cap is $201.19 million.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.29). On average, analysts anticipate that Agile Therapeutics Inc. will post ($1.08) EPS for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP increased its stake in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent filing with the SEC.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.